机构:[1]Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Hepatobiliary Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China.[3]Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen, China.
This work was supported by The National Science Foundation for Excellent Young Scholars, 32122052, National Natural Science Foundation
Regional Innovation and Development, U19A2003, China Postdoctoral Science Foundation, 2022M712244, and Sichuan Provincial Natural Science
Foundation for Young Scholars, 2024NSFSC1748.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|1 区生物学
小类|1 区细胞生物学
最新[2025]版:
大类|1 区生物学
小类|1 区细胞生物学
第一作者:
第一作者机构:[1]Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.[2]Department of Hepatobiliary Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Bi Zhenfei,Ren Wenyan,Zeng Hao,et al.LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants[J].Cell Proliferation.2025,e70060.doi:10.1111/cpr.70060.
APA:
Bi Zhenfei,Ren Wenyan,Zeng Hao,Zhou Yuanyuan,Liu Jian...&Wei Xiawei.(2025).LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.Cell Proliferation,,
MLA:
Bi Zhenfei,et al."LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants".Cell Proliferation .(2025):e70060